• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2019年冠状病毒病的中药疗效与安全性:系统评价与荟萃分析方案

Efficacy and safety of Chinese herbal medicine for Coronavirus disease 2019: A protocol for systematic review and meta-analysis.

作者信息

Yang Maoyi, Hu Zhipeng, Yue Rensong

机构信息

Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, P.R. China.

出版信息

Medicine (Baltimore). 2020 May 29;99(22):e20157. doi: 10.1097/MD.0000000000020157.

DOI:10.1097/MD.0000000000020157
PMID:32481380
Abstract

BACKGROUND

Coronavirus disease 2019 (COVID-19) is a global pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). There is no specific cure for this disease, and the clinical management mainly depends on supportive treatment. Traditional Chinese medicines (CHM) is widely used in treating COVID-19 in China.

METHODS

A comprehensive literature search will be conducted. Two methodological trained researchers will read the title, abstract, and full texts and independently select the qualified literature according to inclusion and exclusion criteria. After assessment of the risk of bias and data extraction, we will conduct meta-analyses for outcomes related to COVID-19. The heterogeneity of data will be investigated by Cochrane χ and I tests. Then publication bias assessment will be conducted by funnel plot analysis and Egger test.

RESULTS

The results of our research will be published in a peer-reviewed journal.

CONCLUSION

Our study aims to systematically present the clinical evidence of CHM in the treatment of COVID-19, which will be of guiding significance for further research and clinical practice.

OSF REGISTRATION NUMBER

10.17605/OSF.IO/H7GMU.

摘要

背景

2019冠状病毒病(COVID-19)是由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的全球大流行疾病。该疾病尚无特效治疗方法,临床管理主要依赖支持性治疗。中药在中国被广泛用于治疗COVID-19。

方法

将进行全面的文献检索。两名经过方法学培训的研究人员将阅读标题、摘要和全文,并根据纳入和排除标准独立选择合格文献。在评估偏倚风险和进行数据提取后,我们将对与COVID-19相关的结局进行荟萃分析。将通过Cochrane χ²和I²检验研究数据的异质性。然后通过漏斗图分析和Egger检验进行发表偏倚评估。

结果

我们的研究结果将发表在同行评审期刊上。

结论

我们的研究旨在系统地呈现中药治疗COVID-19的临床证据,这将对进一步的研究和临床实践具有指导意义。

开放科学框架注册号

10.17605/OSF.IO/H7GMU。

相似文献

1
Efficacy and safety of Chinese herbal medicine for Coronavirus disease 2019: A protocol for systematic review and meta-analysis.2019年冠状病毒病的中药疗效与安全性:系统评价与荟萃分析方案
Medicine (Baltimore). 2020 May 29;99(22):e20157. doi: 10.1097/MD.0000000000020157.
2
Therapeutic efficacy of Qingfei Paidu decoction combined with antiviral drugs in the treatment of corona virus disease 2019: A protocol for systematic review and meta analysis.清肺排毒汤联合抗病毒药物治疗新型冠状病毒肺炎的疗效:系统评价与Meta分析方案
Medicine (Baltimore). 2020 May 29;99(22):e20489. doi: 10.1097/MD.0000000000020489.
3
Effects of weifuchun tablet for chronic atrophic gastritis: A protocol for systematic review and meta-analysis.胃复春片治疗慢性萎缩性胃炎的效果:一项系统评价与Meta分析方案
Medicine (Baltimore). 2020 May 29;99(22):e20374. doi: 10.1097/MD.0000000000020374.
4
[Chinese herbal medicine for side effects of transarterial chemoembolization in liver cancer patients: a systematic review and meta-analysis].[中药治疗肝癌患者经动脉化疗栓塞术副作用的系统评价与Meta分析]
Zhong Xi Yi Jie He Xue Bao. 2012 Dec;10(12):1341-62. doi: 10.3736/jcim20121204.
5
Efficacy and safety of Lian-Hua Qing-Wen granule for COVID-2019: A protocol for systematic review and meta-analysis.连花清瘟颗粒治疗新型冠状病毒肺炎的疗效与安全性:系统评价与Meta分析方案
Medicine (Baltimore). 2020 Jun 5;99(23):e20203. doi: 10.1097/MD.0000000000020203.
6
Single Herbal Medicine for Insulin Resistance: Protocol for a Systematic Review and Meta-Analysis of Randomized Clinical Trials.用于胰岛素抵抗的单味草药:随机临床试验系统评价与Meta分析方案
JMIR Res Protoc. 2025 Jun 10;14:e68915. doi: 10.2196/68915.
7
Adjunctive rifampin therapy for diabetic foot osteomyelitis: A protocol for systematic review and meta-analysis.利福平辅助治疗糖尿病足骨髓炎:一项系统评价与荟萃分析方案
Medicine (Baltimore). 2020 May 29;99(22):e20375. doi: 10.1097/MD.0000000000020375.
8
Efficacy and safety of Xiyanping for COVID-2019: A protocol for systematic review and meta-analysis.喜炎平治疗新型冠状病毒肺炎的疗效与安全性:一项系统评价与荟萃分析方案
Medicine (Baltimore). 2020 Nov 13;99(46):e22962. doi: 10.1097/MD.0000000000022962.
9
Comparative efficacy of Chinese herbal injections for treating severe pneumonia: A protocol for systematic review and Bayesian network meta-analysis of randomized controlled trials.中药注射剂治疗重症肺炎的疗效比较:系统评价和贝叶斯网状Meta 分析的研究方案。
PLoS One. 2022 May 23;17(5):e0262776. doi: 10.1371/journal.pone.0262776. eCollection 2022.
10
Chinese herbal medicines for unexplained recurrent miscarriage.用于不明原因复发性流产的中草药。
Cochrane Database Syst Rev. 2016 Jan 14;2016(1):CD010568. doi: 10.1002/14651858.CD010568.pub2.

引用本文的文献

1
Ozone as an adjuvant therapy for COVID-19: A systematic review and meta-analysis.臭氧辅助治疗 COVID-19:系统评价和荟萃分析。
Int Immunopharmacol. 2022 Sep;110:109014. doi: 10.1016/j.intimp.2022.109014. Epub 2022 Jul 4.
2
Safety and efficacy of ozone therapy in mild to moderate COVID-19 patients: A phase 1/11 randomized control trial (SEOT study).臭氧治疗轻度至中度 COVID-19 患者的安全性和有效性:一项 1/11 期随机对照试验(SEOT 研究)。
Int Immunopharmacol. 2021 Feb;91:107301. doi: 10.1016/j.intimp.2020.107301. Epub 2020 Dec 23.

本文引用的文献

1
Clinical Characteristics of Covid-19 in New York City.纽约市新冠肺炎的临床特征
N Engl J Med. 2020 Jun 11;382(24):2372-2374. doi: 10.1056/NEJMc2010419. Epub 2020 Apr 17.
2
Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2).连花清瘟对新型冠状病毒(SARS-CoV-2)具有抗病毒和抗炎作用。
Pharmacol Res. 2020 Jun;156:104761. doi: 10.1016/j.phrs.2020.104761. Epub 2020 Mar 20.
3
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
羟氯喹和阿奇霉素治疗 COVID-19:一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
4
Treatment for severe acute respiratory distress syndrome from COVID-19.新型冠状病毒肺炎所致严重急性呼吸窘迫综合征的治疗
Lancet Respir Med. 2020 May;8(5):433-434. doi: 10.1016/S2213-2600(20)30127-2. Epub 2020 Mar 20.
5
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病:考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
6
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
7
COVID-19, a pandemic or not?新冠疫情,算不算大流行?
Lancet Infect Dis. 2020 Apr;20(4):383. doi: 10.1016/S1473-3099(20)30180-8. Epub 2020 Mar 13.
8
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素:一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
9
Comorbidities and multi-organ injuries in the treatment of COVID-19.新型冠状病毒肺炎治疗中的合并症与多器官损伤
Lancet. 2020 Mar 21;395(10228):e52. doi: 10.1016/S0140-6736(20)30558-4. Epub 2020 Mar 11.
10
Cardiorenal risk reduction guidance in diabetes: can we reach consensus?糖尿病中心肾风险降低指南:我们能达成共识吗?
Lancet Diabetes Endocrinol. 2020 May;8(5):357-360. doi: 10.1016/S2213-8587(20)30062-0. Epub 2020 Mar 11.